(1). TO ESTABLISH CLINICAL TRIAL NETWORKS (CTNS) AND STRENGTHENING HOSPITAL BASED TRIAL CAPACITY IN OPHTHALMOLOGY (UNDER NATIONAL BIOPHARMA MISSION) – DR. MANABJYOTI BARMAN, SENIOR CONSULTANT, SSN
(2). A GLOBAL, PHASE III, DOUBLE BLIND, RANDOMIZED CONTROLLED STUDY TO COMPARE THE EFFICACY, SAFETY & IMMUNOGENICITY OF LUBT010 WITH LUCENTIS® IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. - PI = DR. MANABJYOTI BARMAN, ICMR PROJECT, 3 YEARS, just started)
(3). LUMINA: A PHASE III, MULTICENTER, SHAM-CONTROLLED, RANDOMIZED, DOUBLE-MASKED STUDY ASSESSING THE EFFICACY AND SAFETY OF INTRAVITREAL INJECTIONS OF 440 µG DE-109 FOR THE TREATMENT OF ACTIVE, NON-INFECTIOUS UVEITIS OF THE POSTERIOR SEGMENT OF THE EYE – PI - DR. DIPANKAR DAS
(4). EVALUATION OF H2S LEVEL IN VITREOUS, AQUEOUS AND PLASMA OF PATIENTS SUFFERING FROM DIABETIC RETINOPATHY AND ITS RELATION WITH GLUCOSE LEVEL IN CELLS. – PI = DR. MANABJYOTI BARMAN, ICMR PROJECT, 2 YEARS, RS. 19,90,000/-
(5). A DOUBLE-MASKED, PLACEBO CONTROLLED, RANDOMIZED, PHASE II CLINICAL TRIAL TO ASSESS THE EFFICACY OF IVIEW – 1201 IN THE TREATMENT OF ACUTE ADENOVIRAL CONJUNCTIVITIS- PI = DR BAL MUKUND AGARWAL, EXCEL LIFE SCIENCE PVT. LTD., 10 MONTHS, RS. 8,31,550/-.
(6). A MULTI-CENTRE STUDY OF ACCESSING CHILDHOOD CANCER SERVICES IN INDIA (ACCESS INDIA STUDY) – PI = DR MANABJYOTI BARMAN
(7). TRANSLATING RESEARCH INTO CLINICAL AND COMMUNITY PRACTICE: A MULTI-CENTRE STATISTICAL AND ECONOMICAL MODELLING OF RISK-BASED STRATIFIED AND PERSONALIZED SCREENING FOR COMPLICATIONS OF DIABETES IN INDIA (SMART INDIA), VISION RESEARCH FOUNDATION, CHENNAI, INDIA – PI = DR HARSHA BHATTACHARJEE, 3 YEARS, RESEARCH COUNCIL UK THROUGH THE MRC UK., MOORFIELDS EYE HOSPITAL, LONDON, VISION RESEARCH FOUNDATION, CHENNAI, INDIA, RS. 10,50,000/-
(8). A SURVEY OF VISUAL IMPAIRMENT AMONG CHILDREN IN BLIND SCHOOL IN NORTHEAST INDIA. – PI = DR DAMARIS MAGDALENE
(9). A PHASE III, MULTINATIONAL, MULTICENTRE, RANDOMIZED, DOUBLE-MASKED STUDY ASSESSING THE SAFETY AND EFFICACY OF INTRA-VITREAL INJECTIONS OF DE-109 (THREE DOSES) FOR THE TREATMENT OF ACTIVE, NON-INFECTIOUS UVEITIS OF THE POSTERIOR SEGMENT OF THE EYE. PI = DR. DIPANKAR DAS, EXCEL LIFE SCIENCES PVT. LTD., 2 YEARS, RS. 1,23,180/-
(10). QUARK NAION STUDY QRK207: A PHASE 2/3, RANDOMIZED, DOUBLE MASKED, SHAM-CONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRA-VITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHAEMIC OPTIC NEUROPATHY (NAION). PI = DR. DIPANKAR DAS, QUARK PHARMACEUTICALS, 2 YEARS, RS. 5,27,506/-
(1). BARRIERS AND ENABLERS FOR THE UPTAKE OF CHILDHOOD CATARACT SERVICES, CITY UNIVERSITY LONDON AND ORBIS INDIA COUNTRY OFFICE. PI = DR DAMARIS MAGDALENE
(2). PREVALENCE AND CAUSES OF AMBLYOPIA IN CHILDREN AGED 6 MONTHS TO 16 YEARS IN KAMRUP (METRO) DISTRICT, ICMR PROJECT. PI = DR DAMARIS MAGDALENE
(3). ASSOCIATION BETWEEN STRUCTURAL AND REFRACTIVE COMPONENT OF EYE AND DIABETIC RETINOPATHY - SRIMANTA SANKARADEVA UNIVERSITY OF HEALTH SCIENCES. – PI = DR HARSHA BHATTACHARJEE
(4). CORRELATION OF BIOMEDICAL PARAMETERS HBA IC and LIPID PROFILE AND APO LIPOPROTIENS IN ADULT DIABETIC PATIENTS WITH DIABETIC RETINOPATHY - SRIMANTA SANKARADEVA UNIVERSITY OF HEALTH SCIENCES. – PI = DR KRISHNA GOGOI
(5). A PHASE III, MULTINATIONAL, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, STUDY ASSESSING THE SAFETY AND EFFICACY OF INTRAVITREAL INJECTIONS OF DE-109 (THREE DOSES) FOR THE TREATMENT OF ACTIVE, NON-INFECTIOUS UVEITIS OF THE POSTERIOR SEGMENT OF THE EYE. – PI = DR DIPANKAR DAS
(6). A MULTICENTER, CONTROLLED, SAFETY AND EFFICACY STUDY OF FLUCINOLONE ACETONIDE INTRAVITREAL INSERT IN SUBJECTS WITH CHRONIC, NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE. – PI = DR DIPANKAR DAS
(7). TOPAZ: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN COMBINATION WITH AN INTRAVITREAL ANTI-VEGF AGENT IN SUBJECTS WITH RETINAL VEIN OCCLUSION . – PI = DR RONEL SOIBAM
(8). QRK 207- A PHASE 2/3, RANDOMIZED , DOUBLE- MASKED, SHAM-CONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJRCTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC NEUROPATHY (NAION) ‘ . – PI = DR DIPANKAR DAS
(9). INFLUENCE OF MEDIA OPACITY DUE TO CONGENITAL/DEVELOPMENTAL CATARACT ON THE AXIAL LENGTH OF EYE. – PI = DR HARSHA BHATTACHARJEE
(10). ANALYSIS OF TEAR FILM PARAMETERS AND CONJUNCTIVAL MORPHOLOGY BEFORE AND AFTER UPPER EYE LID BLEPHAROPLASTY. – PI = DR KASTURI BHATTACHARJEE
(11). TO STUDY THE EFFECT OF GENETIC VARIATION IN VASOACTIVE AND ANGIOGENIC FACTORS IN DEVELOPMENT OF RETINOPATHY. – PI = DR KRISHNA GOGOI
(12). EARLY DETECTION OF ORGANISM IN ENDOPHTHALMITIS BY POLYMERASE CHAIN REACTION (PCR) IN A TERTIARY EYE CARE INSTITUTE IN NORTH- EAST INDIA. – PI = DR KRISHNA GOGOI
(13). A STUDY ON THE EFFECT OF SUSCEPTIBLE SNPS IN HTRA 1 (RS 11200638) & ARMS 2(RS 104909240 IN AMD COHORTS IN NORTH EAST REGION OF INDIA. – PI = DR KRISHNA GOGOI
(14). MAGNOLIA : MULTICENTER , NON INTERVENTIONAL EXTENSION STUDY OF THE SAFETY AND EFFICACY OF CLS-TA FOR THE TREATMENT OF MACULAR EDEMA ASSOCIATED WITH NON-INFECTIOUS UVEITIS. – PI = DR DIPANKAR DAS, EXCEL LIFE SCIENCE PVT. LTD., 1 YEAR
(15). TOPAZ: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN COMBINATION WITH AN INTRAVITREAL ANTI-VEGF AGENT IN SUBJECTS WITH RETINAL VEIN OCCLUSION. – PI = DR RONEL SOIBAM, CLEARSIDE BIOMEDICAL LTD., 12 MONTHS
Powered By GenX
